Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs

Inclusion Criteria: * The subjects are voluntary and sign the informed consent form; * ECOG score 0 to 2; * The expected survival time ≥3 months; * Diffuse large B-cell and peripheral T/NK cell non-Hodgkin's lymphomas confirmed with histopathology, and the peripheral T/NK cell lymphomas that are only limited to the following types: peripheral T-cell lymphoma (not otherwise specified), angioimmunobl; * Failure or relapse after at least once of systemic treatment, and patients who can not receive autologous peripheral blood stem cell transplantation * The major diameter of a single measurable lesion ≥1.5 cm in at least one measurable lesion; * An interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs; * Subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation); * Laboratory tests (blood routine, liver and kidney function) meet the following requirements: * ANC≥ 1.5×109/L, for those with bone marrow involvement, ANC ≥ 1.0×109/L; * PLT ≥ 75×109/L, for those with bone marrow involvement, PLT ≥ 50 × 109/L; * Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ; * TBIL ≤ 1.5x ULN; * AST or ALT ≤2.5 x ULN (for patients with liver metastases, ≤ 5 x ULN ). Exclusion Criteria: * Pregnant or lactating women; * An allergic history to anthracyclines or liposome drugs; * Disease progression or recurrence after anthracycline treatment within six months before the enrollment;" * Patients who once used mitoxantrone injection; * Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose\> 360mg/m2, or epirubicin with the total cumulative dose \> 600mg/m2; * Left ventricular ejection fraction is \< 50% or \< the lower limit of normal; clinically significant QT interval prolongation (\>450ms in male, \>470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease; * Concomitant treatment as other anticancer drugs are needed; * Lymphoma involving the central nervous system; * Clinically active infection that can significantly affect the clinical trial; * Within 6 weeks after organ transplantation or major organ surgery; * Those who are inappropriate to be enrolled as evaluated by the researchers.